If approved, healthcare professionals will be able to prescribe either Xarelto 10mg after patients have received at least 6 months of standard anticoagulation therapy Janssen has submitted a ...

Samuel Z. Goldhaber, MD: Hello. This is Dr. Sam Goldhaber for the Clot Blog on theheart.org talking to you from Brigham and Women's Hospital in Harvard Medical School. The topic today is the safety of ...

In patients with venous thromboembolism who have completed 6–12 months of anticoagulation therapy and are in equipoise for continued anticoagulation, rivaroxaban treatment was associated with lower ...

RARITAN, NJ, Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved XARELTO® to reduce the risk of stroke and systemic embolism in patients with ...

Pexidartinib is an oral small molecule that is believed to work by inhibiting colony stimulating factor-1 receptor (CSF1R). Both doses of Xarelto (10mg and 20mg) were superior to aspirin (100mg) in ...

Therapeutic-dose anticoagulation primarily consisting of rivaroxaban (Xarelto; Bayer/Janssen), compared with standard thromboprophylaxis, does not improve outcomes in patients hospitalized with ...

FDA Approves XARELTO® (rivaroxaban) to Treat Deep Vein Thrombosis and Pulmonary Embolism, and to Reduce the Risk of Recurrent Events RARITAN, NJ, November 2, 2012 – Janssen Pharmaceuticals, Inc.

Xarelto, approved in 2011, has rapidly become a blockbuster drug, with more than $1.3 billion in U.S. sales in 2013. Those sales are due in large part to the drug's recommended once-a-day dosage, less ...

The Food and Drug Administration has given Janssen the green light for two pediatric indications for Xarelto (rivaroxaban): the treatment of venous thromboembolism and reduction in the risk of ...

(CBS/AP) The FDA has approved a "next generation" blood thinner called Xarelto for the treatment of atrial fibrillation, a common heart disorder that can lead to stroke. Atrial fibrillation, a.k.a.

The quality and depth of clinical trials of the blood-thinner Xarelto could be a key issue when the first trials over the drug begin in Philadelphia courtrooms. With the first trial of more than 800 ...